- Compugen (CGEN) +4.8% premarket after announcing a study of its CGEN-15001 Fc fusion protein drug candidate demonstrated high effectiveness in an animal model of autoimmune type I diabetes.
- The study suggests the drug turns off the autoimmune process and may potentially lead to restoration of immune tolerance and resolution of autoimmunity, arresting disease progression.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Fri, 9:57AM)
at CNBC.com (Feb 25, 2014)
at CNBC.com (Sep 3, 2013)
at MarketWatch.com (Aug 5, 2013)
at MarketWatch.com (May 19, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs